Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: An in vitro pharmacodynamic investigation

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 2, 2013, Pages 155-164

  Ferreiro, José L ^a,b   Ueno, Masafumi ^a   Tello Montoliu, Antonio ^a   Tomasello, Salvatore D ^a   Capodanno, Davide ^a   Capranzano, Piera ^a   Dharmashankar, Kodlipet ^a   Darlington, Andrew ^a   Desai, Bhaloo ^a   Rollini, Fabiana ^a   Guzman, Luis A ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antiplatelet agents; Cangrelor; Diabetes mellitus; P2Y12 receptor; Platelet inhibition

Indexed keywords

CANGRELOR; PURINERGIC P2Y12 RECEPTOR; THROMBIN;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY;

ADENOSINE MONOPHOSPHATE; AGED; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84877019071     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0846-z     Document Type: Article

References (40)

1. Geisler T, Anders N, Paterok M et al (2007) Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 30:372-374
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430-2435
3. Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J (2008) Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 100:76-82
4. Lüscher TF, Creager MA, Beckman JA, Cosentino F (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation 108:1655-1661
5. Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123:798-813
6. Ferreiro JL, Cequier ÁR, Angiolillo DJ (2010) Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. Diab Vasc Dis Res 7:274-288
7. Ueno M, Ferreiro JL, Tomasello SD et al (2011) Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost 105:730-732
8. Gurbel PA, Bliden KP, Guyer K, Aggarwal N, Tantry US (2007) Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 119:563-570
9. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C (2003) Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 23:1941-1947
10. van der Meijden PE, Feijge MA, Giesen PL, Huijberts M, van Raak LP, Heemskerk JW (2005) Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 93:1128-1136
11. Angiolillo DJ, Capranzano P, Desai B et al (2009) Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 124:318-322
12. Ferreiro JL, Ueno M, Angiolillo DJ (2009) Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 7:1195-1201
13. Storey RF, Oldroyd KG, Wilcox RG (2001) Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85:401-407
14. Storey RF, Wilcox RG, Heptinstall S (2002) Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 13:407-413
15. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
16. Harrington RA, Stone GW, McNulty S et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318-2329
17. Bhatt DL, Lincoff AM, Gibson CM, CHAMPION PLATFORM Investigators et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330-2341
18. Bouman HJ, van Werkum JW, Hackeng CM, Clappers N, Ten Berg JM (2009) Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. Neth Heart J 17:195-198
19. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3:85-92
20. Angiolillo DJ, Shoemaker SB, Desai B et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 115:708-716
21. Sibbing D, Braun S, Jawansky S et al (2008) Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 99:121-126
22. Ueno M, Ferreiro JL, Tomasello SD et al (2011) Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv 4:905-912
23. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E (2005) Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 3:2039-2043
24. Ferreiro JL, Angiolillo DJ (2012) New directions in antiplatelet therapy. Circ Cardiovasc Interv 5:433-445
25. James S, Angiolillo DJ, Cornel JH, PLATO Study Group et al (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 31:3006-3016
26. Wiviott SD, Braunwald E, Angiolillo DJ, TRITON-TIMI 38 Investigators et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118:1626-1636
27. Angiolillo DJ, Badimon JJ, Saucedo JF et al (2011) A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-3 trial. Eur Heart J 32:838-846
28. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S (2000) The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 110:925-934
29. Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J, Hamm HE (2006) PAR4, but not PAR1, signals human platelet aggregation via Ca2 + mobilization and synergistic P2Y12 receptor activation. J Biol Chem 281:26665-26674
30. Srinivasan S, Mir F, Huang JS, Khasawneh FT, Lam SC, Le Breton GC (2009) The P2Y12 antagonists, 2-methylthioadenosine 5′-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem 284:16108-16117
31. Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD (2011) Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 9:2103-2105
32. Armstrong PC, Leadbeater PD, Chan MV et al (2011) In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 9:552-561
33. Angiolillo DJ, Capranzano P, Ferreiro JL et al (2011) Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 106:253-262
34. Hayashi H, Sudo T (2009) Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 102:327-335
35. Gachet C, Léon C, Hechler B (2006) The platelet P2 receptors in arterial thrombosis. Blood Cells Mol Dis 36:223-227
36. White H, Chew DP, Dauerman HL et al (2012) Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 163:182-190
37. Angiolillo DJ, Firstenberg MS, Price MJ et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307:265-274
38. Angiolillo DJ, Schneider DJ, Bhatt DL et al (2012) Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 34:44-55
39. Leonardi S, Mahaffey KW, White HD et al (2012) Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 163(768-776):e2
40. Roberts HR, Hoffman M, Monroe DM (2006) A cell-based model of thrombin generation. Semin Thromb Hemost 32(Suppl 1):32-38